PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
Market segmentation by application
Comparison by application
Antiviral – Market size and forecast 2018-2023
Antibacterial – Market size and forecast 2018-2023
Antifungal – Market size and forecast 2018-2023
Antiparasitic – Market size and forecast 2018-2023
Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America – Market size and forecast 2018-2023
Europe – Market size and forecast 2018-2023
Asia – Market size and forecast 2018-2023
ROW – Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Increase in R&D of therapeutic vaccines
Increased disease diagnostic modalities
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co Inc.
Pfizer Inc.
Sanofi
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Application – Market share 2018-2023 (%)
Exhibit 18: Comparison by application
Exhibit 19: Antiviral – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antiviral – Year-over-year growth 2019-2023 (%)
Exhibit 21: Antibacterial – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antibacterial – Year-over-year growth 2019-2023 (%)
Exhibit 23: Antifungal – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antifungal – Year-over-year growth 2019-2023 (%)
Exhibit 25: Antiparasitic – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antiparasitic – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by application
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Some of the late-stage molecules
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Therapeutic vaccines
Exhibit 44: Some of the recent POC diagnostics approvals in the US
Exhibit 45: Some of the recently approved combination therapy drugs
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Gilead Sciences, Inc. – Vendor overview
Exhibit 52: Gilead Sciences, Inc. – Business segments
Exhibit 53: Gilead Sciences, Inc. – Organizational developments
Exhibit 54: Gilead Sciences, Inc. – Geographic focus
Exhibit 55: Gilead Sciences, Inc. – Segment focus
Exhibit 56: Gilead Sciences, Inc. – Key offerings
Exhibit 57: GlaxoSmithKline plc – Vendor overview
Exhibit 58: GlaxoSmithKline plc – Business segments
Exhibit 59: GlaxoSmithKline plc – Organizational developments
Exhibit 60: GlaxoSmithKline plc – Geographic focus
Exhibit 61: GlaxoSmithKline plc – Segment focus
Exhibit 62: GlaxoSmithKline plc – Key offerings
Exhibit 63: GlaxoSmithKline plc – Key offerings
Exhibit 64: Merck & Co Inc. – Vendor overview
Exhibit 65: Merck & Co Inc. – Business segments
Exhibit 66: Merck & Co Inc. – Organizational developments
Exhibit 67: Merck & Co Inc. – Geographic focus
Exhibit 68: Merck & Co Inc. – Segment focus
Exhibit 69: Merck & Co Inc. – Key offerings
Exhibit 70: Pfizer Inc. – Vendor overview
Exhibit 71: Pfizer Inc. – Business segments
Exhibit 72: Pfizer Inc. – Organizational developments
Exhibit 73: Pfizer Inc. – Geographic focus
Exhibit 74: Pfizer Inc. – Segment focus
Exhibit 75: Pfizer Inc. – Key offerings
Exhibit 76: Sanofi – Vendor overview
Exhibit 77: Sanofi – Business segments
Exhibit 78: Sanofi – Organizational developments
Exhibit 79: Sanofi – Geographic focus
Exhibit 80: Sanofi – Segment focus
Exhibit 81: Sanofi – Key offerings
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
【掲載企業】
Gilead Sciences, Inc.
GlaxoSmithKline plc
Merck & Co Inc.
Pfizer Inc.
Sanofi
【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。